SCHEMBL4516532

SCHEMBL4516532

Cc1cccc(C)c1OCC(C)NS(=O)(=O)c1ccc(Oc2ccc(F)cc2)cc1

nearest known ligand 0.57

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NR3C1 P04150 3/20 0.57
TSHR P16473 1/20 0.46
FFAR1 O14842 1/20 0.44
FFAR4 Q5NUL3 1/20 0.44
CACNA1H O95180 2/20 0.43
CACNA1B Q00975 2/20 0.43
HTR7 P34969 1/20 0.42
MMP9 P14780 3/20 0.42
SMN1; SMN2 Q16637 1/20 0.41
ADAMTS4 O75173 2/20 0.41
MMP1 P03956 2/20 0.40
MMP2 P08253 2/20 0.40
MMP13 P45452 2/20 0.40
ALDH1A1 P00352 1/20 0.40
POLB P06746 1/20 0.40
MMP3 P08254 1/20 0.40
MMP7 P09237 1/20 0.40
SOS1 Q07889 1/20 0.40
SCN4A P35499 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13889013 0.91 NR3C1 (0.59) NR3C1TSHRMMP9SMN1; SMN2ADAMTS4
SCHEMBL4509097 0.91 NR3C1 (0.59) NR3C1FFAR1MMP9SMN1; SMN2ADAMTS4
SCHEMBL4506870 0.85 NR3C1 (0.62) NR3C1FFAR4HTR7MMP9SMN1; SMN2
SCHEMBL4518778 0.84 NR3C1 (0.57) NR3C1TSHRFFAR4MMP9MMP1
SCHEMBL4511681 0.82 NR3C1 (0.58) NR3C1TSHRSMN1; SMN2ADAMTS4MMP1
SCHEMBL4519626 0.82 NR3C1 (0.53) NR3C1TSHRMMP9SMN1; SMN2ADAMTS4
SCHEMBL4517748 0.82 NR3C1 (0.61) NR3C1TSHRFFAR1FFAR4SMN1; SMN2
SCHEMBL4515277 0.82 NR3C1 (0.63) NR3C1TSHRMMP9SMN1; SMN2MMP1
SCHEMBL4516008 0.81 NR3C1 (0.59) NR3C1TSHRHTR7MMP9ADAMTS4
SCHEMBL13889061 0.81 NR3C1 (0.46) NR3C1TSHRFFAR1FFAR4CACNA1H

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090093485-A1 Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases ASTRAZENECA AB (SE) 2009-04-09 US disclosed
US-20090093485-A1 Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases ASTRAZENECA AB (SE) 2009-04-09 US disclosed
US-20090093485-A1 Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases ASTRAZENECA AB (SE) 2009-04-09 US disclosed
EP-1807391-A1 NOVEL SULPHONAMIDE DERIVATIVES AS GLUCOCORTICOID RECEPTOR MODULATORS FOR THE TREATMENT OF INFLAMMATORY DISEASES AstraZeneca AB (SE) 2007-07-18 EP disclosed
WO-2006046916-A1 NOVEL SULPHONAMIDE DERIVATIVES AS GLUCOCORTICOID RECEPTOR MODULATORS FOR THE TREATMENT OF INFLAMMATORY DISEASES ASTRAZENECA AB (SE) 2006-05-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090093485-A1 Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases NR3C1, NR3C2, NR5A1 NR3C1 1/4885TSHR 686/4885FFAR1 107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.